Gousay Alkhazmari
Gousay Alkhazmari has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Abdulmohsen AlMusaad
King Abdulaziz Medical City -National Guard Health Affairs, Riyadh, Saudi Arabia
1 shared publication - Abdulrahman A Alarfaj1 shared publication
- Aftab Ahmed Jalbani
King Abdulaziz Hospital; National Guard Health Affairs, Saudi Arabia
1 shared publication - Gomaa Abdelrazek
Department of Cardiology, Faculty of Medicine, Fayoum University, Fayoum, Egypt
1 shared publication - Hassan M. Ebeid
Department of Cardiology, Faculty of Medicine, Fayoum University, Fayoum, Egypt
1 shared publication - Hussain Alrowaily1 shared publication
Latest Publications
- Open Access
- 29 July 2026
- Published by Springer Nature in Journal of Cardiovascular Imaging
- Vol. 34 (1) , 22
Assessing myocardial work to predict left ventricular remodeling after ST-segment elevation myocardial infarction: associations with left atrial and left ventricular strain
Background: Left ventricular ejection fraction (LVEF) is the standard marker for systolic function, but it fails to detect subtle changes in myocardial contractility in patients after an ST-elevation myocardial infarction (STEMI). Thus, a new way to evaluate left ventricular (LV) function with high precision is needed to assess disease progression and guide therapeutic interventions. This study evaluates the prognostic significance of left atrial (LA) strain, LV strain, and myocardial work in patients who have undergone primary percutaneous coronary intervention (pPCI) post-STEMI. Methods: The study population was 100 patients diagnosed with STEMI, all of whom received pPCI for their first STEMI event. Patients were admitted to one of two centers, the cardiology department of Fayoum University in Egypt or the cardiac center at King Fahd University Hospital in Saudi Arabia, between November 2022 and March 2024. Conventional echocardiography and 2D speckle-tracking echocardiography (2D-STE) were performed on each participant within 24 h after pPCI and then repeated at least 6 months later. Myocardial work parameters, the global work index, global constructive work (GCW), global wasted work, and global work efficiency and LA strain parameters were derived from 2D-STE and analyzed for their association with subsequent LV remodeling. Results: Myocardial work parameters (e.g., global longitudinal strain) were associated with LV remodeling after STEMI treated with pPCI, with GCW showing the most significant association with LV remodeling among the myocardial work indices evaluated. Furthermore, LV remodeling was associated with significantly impaired cardiac structure and function. Patients who developed LV remodeling exhibited higher LV volumes, lower LVEFs, impaired myocardial work parameters, and longer door-to-balloon times than those without remodeling. Additionally, LA function (e.g., LA ejection fraction) was significantly compromised in the remodeling group. Conclusions: Myocardial work and strain parameters were associated with LV remodeling after STEMI treated with pPCI. GCW demonstrated the strongest association with LV remodeling in the present cohort.
- 29 July 2026
- Published by Springer Nature in Journal of Cardiovascular Imaging
- Vol. 34 (1) , 22
Open AccessAssessing myocardial work to predict left ventricular remodeling after ST-segment elevation myocardial infarction: associations with left atrial and left ventricular strain
Background: Left ventricular ejection fraction (LVEF) is the standard marker for systolic function, but it fails to detect subtle changes in myocardial contractility in patients after an ST-elevation myocardial infarction (STEMI). Thus, a new way to evaluate left ventricular (LV) function with high precision is needed to assess disease progression and guide therapeutic interventions. This study evaluates the prognostic significance of left atrial (LA) strain, LV strain, and myocardial work in patients who have undergone primary percutaneous coronary intervention (pPCI) post-STEMI. Methods: The study population was 100 patients diagnosed with STEMI, all of whom received pPCI for their first STEMI event. Patients were admitted to one of two centers, the cardiology department of Fayoum University in Egypt or the cardiac center at King Fahd University Hospital in Saudi Arabia, between November 2022 and March 2024. Conventional echocardiography and 2D speckle-tracking echocardiography (2D-STE) were performed on each participant within 24 h after pPCI and then repeated at least 6 months later. Myocardial work parameters, the global work index, global constructive work (GCW), global wasted work, and global work efficiency and LA strain parameters were derived from 2D-STE and analyzed for their association with subsequent LV remodeling. Results: Myocardial work parameters (e.g., global longitudinal strain) were associated with LV remodeling after STEMI treated with pPCI, with GCW showing the most significant association with LV remodeling among the myocardial work indices evaluated. Furthermore, LV remodeling was associated with significantly impaired cardiac structure and function. Patients who developed LV remodeling exhibited higher LV volumes, lower LVEFs, impaired myocardial work parameters, and longer door-to-balloon times than those without remodeling. Additionally, LA function (e.g., LA ejection fraction) was significantly compromised in the remodeling group. Conclusions: Myocardial work and strain parameters were associated with LV remodeling after STEMI treated with pPCI. GCW demonstrated the strongest association with LV remodeling in the present cohort.
- Open Access
- 20 December 2023
- Published by MDPI AG in Preprints.org
An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies
Background: COVID-19 was initially identified as a respiratory system disorder, but it has been discovered to interact with and influence the cardiovascular system. COVID-19-associated cardiovascular (CV) complications are common, resulting in high acute phase mortality and a large number of morbidities in the chronic phase, thus severely impacting patients' quality of life and health outcomes. Nevertheless, clinical, cellular, and molecular biological factors underlying the pathophysiology of cardiovascular complications associated with COVID-19 are poorly understood. Objective: This review investigates putative underlying clinical factors as well as cellular and molecular biological mechanisms by which COVID-19 leads to acute CV complications, including state-of-the-art genomic sequencing-based findings, assessing the long-term CV consequences of COVID-19, and aiming to shed light on developing strategies for differential diagnosis, risk prognostic stratification, prevention, and clinical management of CV sequlea in COVID-19 patients. Methods: For this purpose, a through review of literature and published data was carried out from first report of COVID-19 till October 2023 to find out a comprehensive account of clinical, cellular and molecular genetic factors underlying COVID-19-associated cardiovascular diseases. Results: We found that the relationship between COVID-19 and CV risk is complex and multifaceted. In addition to acute COVID-19 detertriuos effects, COVID-19 survivors may experience long-term CV effects. We provide a detailed account of the involvement of a large number of genomic alterations, microRNAs, and novel viral as well as host proteins in CVDs associated with COVID-19, which has helped identify some novel drug targets to treat COVID-19-related cardiovascular complications. Conclusions: The relationship between COVID-19 and CV risk is complex and multifaceted. While COVID-19 primarily affects the respiratory system, it can also significantly affect CV health. as compared to classical cardiovascular diseases, there are new clinical, cellular and molecular biological factors in CVDs related to COVID-19, that need specific diagnostic assays, prognostic stratification and treatment modules. Therefore, specail care is must taken to treat cardiovascular diseases associated with COVID-19.
- 20 December 2023
- Published by MDPI AG in Preprints.org
Open AccessAn In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies
Background: COVID-19 was initially identified as a respiratory system disorder, but it has been discovered to interact with and influence the cardiovascular system. COVID-19-associated cardiovascular (CV) complications are common, resulting in high acute phase mortality and a large number of morbidities in the chronic phase, thus severely impacting patients' quality of life and health outcomes. Nevertheless, clinical, cellular, and molecular biological factors underlying the pathophysiology of cardiovascular complications associated with COVID-19 are poorly understood. Objective: This review investigates putative underlying clinical factors as well as cellular and molecular biological mechanisms by which COVID-19 leads to acute CV complications, including state-of-the-art genomic sequencing-based findings, assessing the long-term CV consequences of COVID-19, and aiming to shed light on developing strategies for differential diagnosis, risk prognostic stratification, prevention, and clinical management of CV sequlea in COVID-19 patients. Methods: For this purpose, a through review of literature and published data was carried out from first report of COVID-19 till October 2023 to find out a comprehensive account of clinical, cellular and molecular genetic factors underlying COVID-19-associated cardiovascular diseases. Results: We found that the relationship between COVID-19 and CV risk is complex and multifaceted. In addition to acute COVID-19 detertriuos effects, COVID-19 survivors may experience long-term CV effects. We provide a detailed account of the involvement of a large number of genomic alterations, microRNAs, and novel viral as well as host proteins in CVDs associated with COVID-19, which has helped identify some novel drug targets to treat COVID-19-related cardiovascular complications. Conclusions: The relationship between COVID-19 and CV risk is complex and multifaceted. While COVID-19 primarily affects the respiratory system, it can also significantly affect CV health. as compared to classical cardiovascular diseases, there are new clinical, cellular and molecular biological factors in CVDs related to COVID-19, that need specific diagnostic assays, prognostic stratification and treatment modules. Therefore, specail care is must taken to treat cardiovascular diseases associated with COVID-19.